indication
as of 2026-07-01Schizophrenia and Disorders With Psychotic Features
Competitive landscape
Competitive set
14
7 approved · 7 pipeline
Projection timeline
actual past → guided future · protection walls overlaid
38 events
2020
2024
2028
2032
2036
2040
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff
Competitive set
resolved drugs with trials in this indicationdrugCompleted
US-approved 1986 · Haldol Decanoate
Phase 42 trials
Protection—
drugCompleted
US-approved 2001 · Geodon
Phase 42 trials
Protection—
drugCompleted
US-approved 1996 · ZYPREXA Intramuscular
Phase 41 trial
Protection2041
drugCompleted
US-approved 1993 · RISPERDAL
Phase 41 trial
Protection2042
drugCompleted
US-approved 2006 · Erzofri extended-release
Phase 41 trial
OwnerJohnson & Johnson
Protection2041
drugCompleted
Pipeline · Phase 2
Phase 21 trial
Protection—
drugCompleted
Pipeline · Phase 4
Phase 41 trial
Protection—
drugCompleted
Pipeline · Phase 4
Phase 41 trial
Protection—
Market size
prevalence as a range, not a number